ChiCTR2400089771 版本V1.0 版本创建时间2024/09/14 11:33:39 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400089771 

最近更新日期:

Date of Last Refreshed on:

2024-09-14 11:33:36 

注册时间:

Date of Registration:

2024-09-14 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

非休克脓毒症相关心肌损伤的危险因素和死亡率

Public title:

Risk factors and mortality of non-shock sepsis associated myocardial injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

非休克脓毒症相关心肌损伤的危险因素和死亡率

Scientific title:

Risk factors and mortality of non-shock sepsis associated myocardial injury

研究课题代号(代码):

Study subject ID:

320.21

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

320.21

申请注册联系人:

童道明 

研究负责人:

周业庭 

Applicant:

Tong Dao-Ming 

Study leader:

Zhou Ye-Ting 

申请注册联系人电话:

Applicant telephone:

+86 159 5063 4718

研究负责人电话:

Study leader's
telephone:

+86 015261258819

申请注册联系人传真 :

Applicant Fax:

+86 527 83557553

研究负责人传真:

Study leader's fax:

+86 577 88078262

申请注册联系人电子邮件:

Applicant E-mail:

tongdaoming@163.com

研究负责人电子邮件:

Study leader's E-mail:

ytz@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.shyyy.com/

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

http://www.shyyy.com/

申请注册联系人通讯地址:

江苏省宿迁市沭阳县迎宾大道9号

研究负责人通讯地址:

江苏省宿迁市沭阳县迎宾大道9号

Applicant address:

9 Yingbin Avenue, Shuyang County, Suqian, Jiangsu

Study leader's address:

9 Yingbin Avenue, Shuyang County, Suqian, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

223600

研究负责人邮政编码:

Study leader's postcode:

223600

申请人所在单位:

江苏省徐州医科大学附属沭阳医院

Applicant's institution:

Affiliated Shuyang Hospital of Xuzhou Medical University

研究负责人所在单位:

江苏省徐州医科大学附属沭阳医院

Affiliation of the Leader:

Affiliated Shuyang Hospital of Xuzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SYYYLL202431

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

沭阳医院伦理委员会

Name of the ethic committee:

Shuyang Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-08 00:00:00

伦理委员会联系人:

张华华

Contact Name of the ethic committee:

Zhang Huahua

伦理委员会联系地址:

江苏省宿迁市沭阳县迎宾大道9号

Contact Address of the ethic committee:

9 Yingbin Avenue, Shuyang County, Suqian, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 577 8081 7265

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zhh@163.com

研究实施负责(组长)单位:

江苏省徐州医科大学附属沭阳医院

Primary sponsor:

Affiliated Shuyang Hospital of Xuzhou Medical University

研究实施负责(组长)单位地址:

江苏省宿迁市沭阳县迎宾大道9号

Primary sponsor's address:

9 Yingbin Avenue, Shuyang County, Suqian, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省徐州医科大学附属沭阳医院

具体地址:

江苏省宿迁市沭阳县迎宾大道9号

Institution
hospital:

Affiliated Shuyang Hospital of Xuzhou Medical University

Address:

9 Yingbin Avenue, Shuyang County, Suqian, Jiangsu

经费或物资来源:

徐州医科大学及其他

Source(s) of funding:

Funded by the Xuzhou Meidcal University and others

研究疾病:

非休克脓毒症相关心肌损伤  

Target disease:

Non-shock sepsis associated myocardial injury

研究疾病代码:

| - H0222

Target disease code:

| - H0222

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

研究ICU中非休克脓毒症相关心肌损伤的危险因素和死亡率。  

Objectives of Study:

We aimed to investigate the risk factors and mortality of non-shock sepsis associated myocardial injury(nsSAMI)

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

成年危重患者经ICU之前或之后紧急胸部和腹部或大脑CT筛查,并在初始血液检测快速执行多个心肌酶标志物(MIM)测定而且进ICU >24小时被诊断为非休克脓毒症相关心肌损伤者纳入在这项研究中。

Inclusion criteria

Adult critically ill patients who underwent emergency chest and abdominal or brain CT screening before or after the ICU, rapidly performed multiple myocardial enzyme markers (MIM) measurements on initial blood testing and were diagnosed with non-shock sepsis-related myocardial injury at the ICU for> 24 hours were included in this study.

排除标准:

(1)因家人要求在最初24小时内放弃治疗而死亡或自动退出ICU的患者;(2)因非脓毒症疾病导致MIM升高的患者未纳入本研究。

Exclusion criteria:

(1) We excluded those critical ill patients who were either death or automatically out of the ICU due to family asked to give up treatment within the first 24 hours. (2) Patients with elevated MIM due to non sepsis related diseases were not included in this study.

研究实施时间:

Study execute time:

From 2023-06-01 00:00:00 To 2024-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-02 00:00:00 To 2023-12-31 00:00:00

干预措施:

Interventions:

组别:

非生存组

样本量:

178

Group:

non-survival group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

生存组

样本量:

134

Group:

survival group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省徐州医科大学附属沭阳医院 

单位级别:

三乙 

Institution
hospital:

Affiliated Shuyang Hospital of Xuzhou Medical University

Level of the institution:

Tertiary B

测量指标:

Outcomes:

指标中文名:

发病率和危险因素

指标类型:

主要指标

Outcome:

Morbidity and risk factors

Type:

Primary indicator

测量时间点:

在ICU28天内

测量方法:

Measure time point of outcome:

within 28 days in the ICU

Measure method:

指标中文名:

死亡率

指标类型:

次要指标

Outcome:

Mortality

Type:

Secondary indicator

测量时间点:

进人ICU28 天内

测量方法:

Measure time point of outcome:

within ICU 28 days

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 22 years
最大 Max age 91 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表文章后

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After publishing the paper

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-09-14 11:33:36